23:16 , Oct 6, 2017 |  BioCentury  |  Finance

No EIF, no problem?

In response to uncertainty about access to the European Investment Fund and European Investment Bank following Brexit, the BioIndustry Association is asking the U.K. government to pursue two paths in parallel. BIA wants the government...
08:00 , Jan 25, 2016 |  BioCentury  |  Finance

Venturing to share

Abingworth has seen enough success with its clinical risk-sharing investments that it opted to raise a fund dedicated solely to finding more. Last week, the firm closed its Abingworth Clinical Co-Development fund at $105 million....
07:00 , May 25, 2015 |  BioCentury  |  Finance

Cash cravings

BioCentury's 13th annual European Iceberg survey foresees record financing demand, driven on the public side by higher burn rates and the number of companies joining the group via IPOs, and on the private side by...
03:39 , Dec 6, 2014 |  BC Extra  |  Financial News

von Emster leaving venBio for Abingworth

Longtime biotech portfolio manager and VC Kurt von Emster has departed venBio, which he co-founded in 2009, and will join Abingworth as a partner in January. Abingworth said von Emster will work out of the...
07:00 , May 26, 2014 |  BioCentury  |  Finance

Europe's Iceberg 2014: Divergent appetites

BioCentury's 12th annual European Iceberg survey projects one of the lowest financing demand figures ever for public biotechs, thanks to the robust funding environment over the last two years. But while private companies actually raised...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Financial News

Abingworth financial update

Abingworth closed its tenth life sciences venture fund, Abingworth Bioventures VI, with £225 million ($374.7 million), above the fund's £200 million ($333 million) target. Abingworth said it plans to make investments of £5-£20 million ($8.3-$33.3...
08:00 , Mar 3, 2014 |  BioCentury  |  Finance

Spreading six

Abingworth's sixth flagship fund likely will put more money towards the opposite ends of the firm's investment universe - start-ups and public companies. The new fund closed last week at £225 million ($375 million). Seven...
01:51 , Feb 28, 2014 |  BC Extra  |  Financial News

Abingworth closes L225 million fund

Abingworth closed its tenth life sciences venture fund, Abingworth Bioventures VI, with L225 million ($374.7 million), above the fund's L200 million ($333 million) target. Abingworth said it plans to make investments of L5-L20 million ($8.3-$33.3...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Financial News

Cytos completes private placement of senior convertible notes

Cytos Biotechnology AG (SIX:CYTN), Schlieren, Switzerland   Business: Neurology, Inflammation, Infectious   Date completed: 10/21/13   Type: Private placement of senior convertible notes   Raised: CHF6.6 million ($7.3 million)   Shares outstanding prior: 22.4 million...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Financial News

Avedro completes venture financing

Avedro Inc. , Waltham, Mass.   Business: Ophthalmic   Date completed: 3/5/13   Type: Venture financing   Raised: $43 million   Investors: Abingworth Bioventures; Third Point; Prism VentureWorks; De Novo Ventures; Flagship Ventures; Aperture Ventures;...